公开(公告)号：EP2291078A1

公开(公告)日：2011-03-09

申请号：EP09747248.4

申请日：2009-05-08

申请人： Merck Sharp & Dohme Corp.

发明人： BRNARDIC, Edward, J. ,  CONVERSO, Antonella ,  FRALEY, Mark, E. ,  GARBACCIO, Robert, M. ,  HUANG, Shaei, Y.

IPC分类号： A01N43/50 ,  A01N43/76 ,  A61K31/42

CPC分类号： C07D498/04

摘要： The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

摘要翻译： 本发明涉及作为代谢型谷氨酸受体增效剂的恶唑并苯并咪唑衍生物，特别是mGluR2受体，其可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型谷氨酸受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。